ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Epidemiology and Prevention
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1497691
Retrospective assessment of the frequency of cancer in the population of kidney transplant recipients -the experience of two transplant centers
Provisionally accepted- 1Department of Nephrology, Transplantology and Internal Diseases, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
- 2Department of Nephrology, Transplantology and Internal Medicine, Medical University of Silesia, Katowice, Portugal
- 3Skin and Venereology Clinic, Copernicus Medical Entity, Gdańsk, Poland
- 4Palliative Medicine Facility, Medical University of Gdańsk, Gdańsk, Poland
- 5Department of Internal Medicine and Pediatric Nursing, Faculty of Health Sciences, Medical University of Gdańsk, Gdańsk, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cancer is one of the main causes of death among kidney recipients. The risk of cancer in kidney transplant recipients (KTRs) is 2-3 times higher as compared to the general population.Retrospective assessment of the occurrence of cancer in the population of KTRs -based on data from two transplant centers.The study included a total of 246 KTRs, transplanted between 1980 and 2021, who were diagnosed with malignancy (the study did not include patients whose only cancer was non-melanoma skin cancer; NMSC). RESULTS: 261 malignant tumors were diagnosed in 246 KTRs, 3 tumor was a recurrence, and the rest occurred de novo. The most common cancers in women were breast cancers (17.8%), colon cancers (14.5%), lung cancers and post-transplant lymphoproliferative disorder (PTLD) (8.9% each). In males, the most common cancers were native kidney cancer (16.4%), lung cancer (15.7%) and prostate cancer (14%). During the study period, among KTRs who developed solid organ malignancy, NMSC was diagnosed in 7.3% of recipients. The average time of occurrence of malignant tumors was 84.5 months/7 years after kidney transplantation (KTx), and most cancers developed in the range of 1-5 years (33.6%) and 5-10 years (34.42%) after KTx.Nearly half (48.8%) of patients died due to cancer.Similarly to the general population, the most common cancers among KTRs included breast and prostate cancer, as well as colorectal and lung cancer. Attention should be paid to the extremely frequent occurrence of native kidney and lymphatic system cancers in this group of KTRs.
Keywords: Kidney transplant, malignacies, Recipients, Cancer, Kidney recipients
Received: 17 Sep 2024; Accepted: 14 May 2025.
Copyright: © 2025 Komorowska-Jagielska, Debska-Slizien, Kolonko, Heleniak, Ruszkowski, Imko-Walczuk, Biedunkiewicz, Bullo-Piontecka, Bzoma, Chamienia, Gołębiewska, Konopa, Krol, Lichodziejewska-Niemierko, Rutkowski, Tarasewicz, Wiecek and Lizakowski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Karolina Komorowska-Jagielska, Department of Nephrology, Transplantology and Internal Diseases, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
Alicja Debska-Slizien, Department of Nephrology, Transplantology and Internal Diseases, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
Zbigniew Heleniak, Department of Nephrology, Transplantology and Internal Diseases, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.